JP2018511643A - 癌を治療するための方法 - Google Patents

癌を治療するための方法 Download PDF

Info

Publication number
JP2018511643A
JP2018511643A JP2017554403A JP2017554403A JP2018511643A JP 2018511643 A JP2018511643 A JP 2018511643A JP 2017554403 A JP2017554403 A JP 2017554403A JP 2017554403 A JP2017554403 A JP 2017554403A JP 2018511643 A JP2018511643 A JP 2018511643A
Authority
JP
Japan
Prior art keywords
cancer
compound
paclitaxel
formula
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017554403A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018511643A5 (enExample
Inventor
リー，チアン，ジェイ．
リー，ウェイ
リー，ヨウジ
ヒトロン，マシュー，ジェイ．
ガオ，ユアン
Original Assignee
ボストン バイオメディカル， インコーポレイテッド
ボストン バイオメディカル， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ボストン バイオメディカル， インコーポレイテッド, ボストン バイオメディカル， インコーポレイテッド filed Critical ボストン バイオメディカル， インコーポレイテッド
Publication of JP2018511643A publication Critical patent/JP2018511643A/ja
Publication of JP2018511643A5 publication Critical patent/JP2018511643A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2017554403A 2015-04-17 2016-04-18 癌を治療するための方法 Pending JP2018511643A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562149349P 2015-04-17 2015-04-17
US62/149,349 2015-04-17
US201662280947P 2016-01-20 2016-01-20
US62/280,947 2016-01-20
PCT/US2016/028177 WO2016168856A1 (en) 2015-04-17 2016-04-18 Methods for treating cancer

Publications (2)

Publication Number Publication Date
JP2018511643A true JP2018511643A (ja) 2018-04-26
JP2018511643A5 JP2018511643A5 (enExample) 2019-04-25

Family

ID=55854799

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017554403A Pending JP2018511643A (ja) 2015-04-17 2016-04-18 癌を治療するための方法

Country Status (16)

Country Link
US (1) US20180085341A1 (enExample)
EP (1) EP3283069A1 (enExample)
JP (1) JP2018511643A (enExample)
KR (1) KR20180006918A (enExample)
CN (1) CN107666906A (enExample)
AU (1) AU2016247319A1 (enExample)
BR (1) BR112017022281A2 (enExample)
CA (1) CA2983010A1 (enExample)
EA (1) EA201792287A1 (enExample)
HK (1) HK1250944A1 (enExample)
IL (1) IL255022A0 (enExample)
MX (1) MX2017013360A (enExample)
PH (1) PH12017501879A1 (enExample)
SG (2) SG11201708504XA (enExample)
TW (1) TW201713327A (enExample)
WO (1) WO2016168856A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024123152A (ja) * 2018-10-12 2024-09-10 １グローブ バイオメディカル カンパニー， リミテッド 化学療法難治性がんの治療のための新しい併用薬方法

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE027443T2 (en) 2007-09-10 2016-10-28 Boston Biomedical Inc A novel class of Stat3 pathway inhibitors and tumor stem cell inhibitors
JP6433085B2 (ja) 2013-04-09 2018-12-05 ボストン バイオメディカル， インコーポレイテッド がんの処置に使用するための２−アセチルナフト［２，３−ｂ］フラン−４，９−ジオン
JP2019506392A (ja) * 2016-01-20 2019-03-07 ボストン バイオメディカル， インコーポレイテッド がんを処置するための方法
US11299469B2 (en) 2016-11-29 2022-04-12 Sumitomo Dainippon Pharma Oncology, Inc. Naphthofuran derivatives, preparation, and methods of use thereof
WO2018213424A1 (en) 2017-05-17 2018-11-22 Boston Biomedical, Inc. Methods for treating cancer
EP3678663A4 (en) * 2017-09-05 2021-06-02 Epizyme, Inc. POLYTHERAPY FOR CANCER TREATMENT
EP3705893A1 (en) * 2019-03-05 2020-09-09 Humanitas Mirasole S.p.A. Methods to assess the risk of being affected by prostate cancer
TW202102207A (zh) * 2019-03-27 2021-01-16 新加坡商新加坡保健服務集團有限公司 對於癌病具有治療意義的生物標記

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010539098A (ja) * 2007-09-10 2010-12-16 ボストン バイオメディカル， インコーポレイテッド 癌治療のための新規の組成物および方法
WO2014169078A2 (en) * 2013-04-09 2014-10-16 Boston Biomedical, Inc. Methods for treating cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103002890A (zh) 2010-03-19 2013-03-27 波士顿生物医学公司 靶向癌症干细胞的新的化合物和组合物
CN103025159A (zh) 2010-03-19 2013-04-03 波士顿生物医学公司 靶向癌症干细胞的新方法
EP2681203A4 (en) 2011-03-04 2014-07-30 Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co Ltd NOVEL 4,9-DIHYDROXY-NAPHTO [2,3-B] FURANS ESTERS FOR THERAPEUTIC TREATMENT OF DISEASES
US8977803B2 (en) 2011-11-21 2015-03-10 Western Digital Technologies, Inc. Disk drive data caching using a multi-tiered memory
WO2013166618A1 (en) * 2012-05-08 2013-11-14 Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co., Ltd. PRODRUGS OF 4,9-DIHYDROXY-NAPHTHO[2,3-b]FURANS FOR CIRCUMVENTING CANCER MULTIDRUG RESISTANCE
JP2019506392A (ja) * 2016-01-20 2019-03-07 ボストン バイオメディカル， インコーポレイテッド がんを処置するための方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010539098A (ja) * 2007-09-10 2010-12-16 ボストン バイオメディカル， インコーポレイテッド 癌治療のための新規の組成物および方法
WO2014169078A2 (en) * 2013-04-09 2014-10-16 Boston Biomedical, Inc. Methods for treating cancer

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
J. HEPATOBILIARY PANCREAT. SCI., vol. 21, JPN6019050063, 2014, pages 767 - 776, ISSN: 0004322767 *
PNAS, vol. 112, no. 6, JPN6019050061, 10 February 2015 (2015-02-10), pages 1839 - 1844, ISSN: 0004322766 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024123152A (ja) * 2018-10-12 2024-09-10 １グローブ バイオメディカル カンパニー， リミテッド 化学療法難治性がんの治療のための新しい併用薬方法

Also Published As

Publication number Publication date
WO2016168856A1 (en) 2016-10-20
IL255022A0 (en) 2017-12-31
CN107666906A (zh) 2018-02-06
HK1250944A1 (zh) 2019-01-18
EA201792287A1 (ru) 2018-03-30
BR112017022281A2 (pt) 2018-07-10
AU2016247319A1 (en) 2017-11-02
MX2017013360A (es) 2018-08-01
TW201713327A (zh) 2017-04-16
KR20180006918A (ko) 2018-01-19
SG10201900564WA (en) 2019-02-27
SG11201708504XA (en) 2017-11-29
EP3283069A1 (en) 2018-02-21
CA2983010A1 (en) 2016-10-20
PH12017501879A1 (en) 2018-03-05
US20180085341A1 (en) 2018-03-29

Similar Documents

Publication Publication Date Title
JP2018511643A (ja) 癌を治療するための方法
JP2020169222A (ja) 癌を治療するための方法
JP2021121629A (ja) Ｓｔａｔ３経路阻害薬およびキナーゼ阻害薬を用いて癌を治療するための方法
US10646464B2 (en) Methods for treating cancer
JP2018511642A (ja) 癌を治療するための方法
WO2018005444A2 (en) Methods for treating cancer
KR20210076951A (ko) 화학요법 불응성 암을 치료하기 위한 신규한 조합 방안
HK1220365A1 (en) Etoposide prodrugs for use in targeting cancer stem cells

Legal Events

Date Code Title Description
RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20190130

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20190214

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190313

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190313

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191219

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200124

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200811